JAZZ - Jazz Pharmaceuticals EPS beats by $0.30 beats on revenue February, 25 2020 04:09 PM Jazz Pharmaceuticals plc Jazz Pharmaceuticals (NASDAQ:JAZZ): Q4 Non-GAAP EPS of $4.42 beats by $0.30; GAAP EPS of $1.29 misses by $0.20.Revenue of $581.74M (+22.1% Y/Y) beats by $21.16M.Shares +0.2%.Press ReleaseMore news on: Jazz Pharmaceuticals plc, Earnings news and commentary, Healthcare stocks news,